BPC-157 vs TB-500: A Side-by-Side Research Comparison

BPC-157 and TB-500 are unrelated peptides that often turn up in the same conversation. BPC-157 is a 15-residue synthetic sequence derived from a human gastric juice protein, studied mostly in models of angiogenesis and nitric-oxide signaling. TB-500 is a synthetic form of thymosin beta-4, a 43-residue actin-binding peptide studied in models of cell migration and actin dynamics. They differ in size, origin, sequence and the main mechanism each has been studied for.

At a glance

Structure and origin

BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic pentadecapeptide. Its originating group describes it as a gastric peptide, formed in the gastric mucosa and stable in human gastric juice [1]. Published mechanistic work describes it through downstream signaling pathways such as eNOS and VEGF signaling [3, 4].

Thymosin β-4 is a naturally occurring 43-residue peptide with an acetylated serine at the N-terminus. It was first sequenced from thymus preparations [2] and later shown to be identical to "Fx," the main actin-sequestering peptide in human platelets [5]. It is found at high concentrations in almost every cell type [7].

A naming caveat applies to TB-500. Some analytical literature uses the name TB-500 for a synthetic seven-residue fragment of thymosin β-4 (Ac-LKKTETQ). Tidal's TB-500 is full-length thymosin β-4 (CAS 77591-33-4, 4963.44 Da), which is why the molecular weight on its COA matches the full peptide. More in TB-500 and thymosin beta-4.

Mechanisms each has been studied for

BPC-157: angiogenesis and nitric oxide

• A review of BPC-157's vascular literature, from its originating group, describes it as acting on blood vessels through several pathways, including nitric oxide, VEGF and FAK [4]. A 2026 critical review of rodent ischemia–reperfusion studies reported changes in VEGF/VEGFR2–Akt–eNOS-related signaling across that literature [8].
• In isolated rat aorta, BPC-157 produced endothelium-dependent, nitric-oxide-mediated vasodilation, and it activated a Src–Caveolin-1–eNOS pathway in endothelial cells [3].
• In isolated human internal mammary artery rings, it produced endothelium-dependent, largely nitric-oxide-mediated relaxation [9].

TB-500 / thymosin β-4: actin and cell migration

• Thymosin β-4 binds monomeric (G-) actin in a 1:1 complex and inhibits its polymerization. This makes it a major regulator of the cellular actin pool [5, 7].
• A structure–function review maps distinct activities to short regions of the molecule. The central actin-binding domain (residues 17–23, LKKTETQ) is associated with cell migration and angiogenesis activity. The review also lists activation of ILK/PINCH/Akt signaling among thymosin β-4's reported activities [6].
• In cell studies, thymosin β-4 interfered with TNF-α-induced NF-κB activation and RelA/p65 nuclear translocation, independently of its G-actin binding. It also counteracted the sensitizing effect of its binding partners PINCH-1 and ILK on NF-κB activity [10].
• In endothelial progenitor cells, thymosin β-4 increased VEGF secretion through an Akt/eNOS-dependent mechanism. Conditioned medium from these cells increased tube formation by human umbilical vein endothelial cells [11].

The two peptides do overlap: both have been examined in vascular and angiogenesis research, and both are linked to Akt signaling in the papers above. Their upstream mechanisms are described differently, though. BPC-157 work points to eNOS, nitric oxide and VEGF signaling, while thymosin β-4 work points to actin binding and the ILK complex.

Strength of the evidence

Both literatures are preclinical. A large share of the in-vivo BPC-157 work comes from one research group, and a 2026 critical review of rodent ischemia–reperfusion studies described the evidence as heterogeneous. It called for independent blinded replication, pharmacokinetic characterization and further preclinical work [8]. Neither peptide is an approved drug. Results from cell and animal models shouldn't be extrapolated beyond those systems.

Analytical notes

Their sizes make the two peptides behave differently in the lab. On reverse-phase HPLC they elute at different retention times, so a combined BPC-157 + TB-500 sample should show two well-separated main peaks. On mass spectrometry, thymosin β-4 usually appears as a series of multiply charged ions, so the COA should report a deconvoluted mass or the specific charge states observed. Thymosin β-4 also has a single methionine at position 6, which can oxidize. Oxidation adds 16 Da and can show up as a satellite peak. The sulfoxide form still sequesters actin in vitro [12], but on a COA it counts as a separate species. See reading a certificate of analysis, HPLC purity explained and the COA registry.

Common questions

Are BPC-157 and TB-500 related molecules?

No. They have unrelated sequences and different origins. BPC-157's sequence is gastric in origin [1], and thymosin β-4 is an endogenous member of the β-thymosin family [7]. They come up together because they are often supplied as a blend, not because they are structurally related.

Is TB-500 the same as thymosin beta-4?

It depends on the supplier. Our TB-500 is full-length thymosin β-4 (4963.44 Da). Some analytical literature uses the name for a synthetic seven-residue fragment, Ac-LKKTETQ. The molecular weight on the COA tells you which one is in the vial.

Storage and handling

Handle both as laboratory material. Store lyophilized vials at −20 °C, away from light and moisture, and let them reach room temperature before opening. After reconstitution, keep solutions at 2–8 °C and avoid repeated freeze–thaw cycles.

For full single-compound profiles, see the BPC-157 research overview and TB-500 and thymosin beta-4.

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PubMed
2. Low TL, Goldstein AL. Chemical characterization of thymosin beta 4. J Biol Chem. 1982. PubMed
3. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020. PubMed
4. Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014. PubMed
5. Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. PubMed
6. Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010. PubMed
7. Huff T, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001. PubMed
8. Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026. PubMed
9. Yildirim AK, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. 2026. PubMed
10. Qiu P, et al. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011. PubMed
11. Zhao Y, et al. Thymosin β4 promotes endothelial progenitor cell angiogenesis via a vascular endothelial growth factor-dependent mechanism. Mol Med Rep. 2018. PubMed
12. Hannappel E, Wartenberg F. Actin-sequestering ability of thymosin beta 4, thymosin beta 4 fragments, and thymosin beta 4-like peptides as assessed by the DNase I inhibition assay. Biol Chem Hoppe Seyler. 1993. PubMed